Cited by 315Erythropoietin and Anemia TreatmentIron Metabolism and DisordersHemoglobin structure and function

The DOI matches its Crossref record; 238 of the 239 references it cites were found in a registry or an index.

Anaemia in kidney disease: harnessing hypoxia responses for therapy

Open access

Koury, Mark J., Haase, Volker H.·2015·Nature Reviews Nephrology

DOI 10.1038/nrneph.2015.82PMC PMC4497972

Open this paper in CoChat — free account

Abstract

Improved understanding of the oxygen-dependent regulation of erythropoiesis has provided new insights into the pathogenesis of anaemia associated with renal failure and has led to the development of novel therapeutic agents for its treatment. Hypoxia-inducible factor (HIF)-2 is a key regulator of erythropoiesis and iron metabolism. HIF-2 is activated by hypoxic conditions and controls the production of erythropoietin by renal peritubular interstitial fibroblast-like cells and hepatocytes. In anaemia associated with renal disease, erythropoiesis is suppressed due to inadequate erythropoietin production in the kidney, inflammation and iron deficiency; however, pharmacologic agents that activate the HIF axis could provide a physiologic approach to the treatment of renal anaemia by mimicking hypoxia responses that coordinate erythropoiesis with iron metabolism. This Review discusses the functional inter-relationships between erythropoietin, iron and inflammatory mediators under physiologic conditions and in relation to the pathogenesis of renal anaemia, as well as recent insights into the molecular and cellular basis of erythropoietin production in the kidney. It furthermore provides a detailed overview of current clinical experience with pharmacologic activators of HIF signalling as a novel comprehensive and physiologic approach to the treatment of anaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrneph.2015.82

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Anemia of Chronic Disease
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549

Show all 239 references

Research works printed but not linked: 12

Yoon, D. et al. HIF-1α-deficiency results in dysregulated EPO signaling and iron homeostasis in mouse development. J. Biol. Chem. 281, 25703–25711 (2006). · DOI
Klaus, S., Langsetmo, I., Neff, T., Lin, A. & Liu, D. beneficial pharmacodynamic effects resulting from 'complete erythropoiesis' induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592 [abstract]. J. Am. Soc. Nephrol. 19, 524A (2008).
Besarab, A., Szczech, L., Yu, K. H. P. & Neff, N. B. Impact of iron regimen on iron indices and hepcidin during roxadustat anemia correction in incident dialysis patients [abstract]. J. Am. Soc. Nephrol. 25, 304A (2014).
Frohna, P. A. et al. Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in subjects with CKD anemia [abstract]. J. Am. Soc. Nephrol. 18, 763A (2007).
Provenzano, R. et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis (HD) patients: phase 2 comparison with epoetin alfa [abstract]. J. Am. Soc. Nephrol. 23, 428A (2012).
Brigandi, R. A. et al. The prolyl hydroxylase inhibitor, GSK1278863A, induced EPO in vitro and efficient erythropoiesis leading to increased hemoglobin in vivo [abstract]. J. Am. Soc. Nephrol. 21, 722A (2010).
Brigandi, R. A. et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract]. J. Am. Soc. Nephrol. 23, 662A (2012).
Shalwitz, R., Hartman, C., Flinn, C., Shalwitz, I. & Logan, D. K. AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults [abstract]. J. Am. Soc. Nephrol. 22, 45A (2011).
Hartman, C. et al. AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia [abstract]. J. Am. Soc. Nephrol. 22, 435A (2011).
Shalwitz, R. et al. AKB-6548: A new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels [abstract]. J. Am. Soc. Nephrol. 23, 56A (2012).
Hartman, C. S. et al. Phase 2 study of AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD). akebia.com [online] , (2014).
Boettcher, M.-F. et al. First-in-man Study with BAY 85–3934—a new oral selective HIF-PH inhibitor for the treatment of renal anemia. J. Am. Soc. Nephrol. 24, 347A (2013).

Sorted by citations

Items 101–200 of 315

Iron and ferroptosis in kidney disease: molecular and metabolic mechanisms
Wang, W., Chen, J., Zhan, L., Zou, H., Wang, L., Guo, M., Gao, H., Xu, J., & Wu, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1531577 · Cited by 28
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis
Li, J., Xie, Q., You, L., Xu, N., & Hao, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105256 · Cited by 24
Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development
Kobayashi, H., Liu, J., Urrutia, A. A., Burmakin, M., Ishii, K. J., Rajan, M., Davidoff, O., Saifudeen, Z. R., & Haase, V. H. (2017) · Kidney International · doi:10.1016/j.kint.2017.06.015 · Cited by 27
Self-citation
Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
Babitt, J. L., Berns, J. S., Bozkurt, B., Khedairy, R. S. C., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.06.005 · Cited by 36
Self-citation
Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation
Zhou, Y., Chen, X., Zhang, Y., Lou, J., & Yuan, H. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02738-4 · Cited by 24
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
Koury, M. J., Agarwal, R., Chertow, G. M., Eckardt, K., Fishbane, S. N., Ganz, T., Haase, V. H., Hanudel, M. R., Parfrey, P. S., Pérgola, P. E., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26644 · Cited by 24
Self-citation
TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver
Kato, S., Ochiai, N., Takano, H., Io, F., Takayama, N., Koretsune, H., Kunioka, E.-I., Uchida, S., & Yamamoto, K. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258731 · Cited by 24
The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials
Abdelazeem, B., Shehata, J., Abbas, K. S., El‐Shahat, N. A., Malik, B. H., Savarapu, P. K., Eltobgy, M. M., & Kunadi, A. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266243 · Cited by 24
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
Yamamoto, H., Taguchi, M., Matsuda, Y., Iekushi, K., Yamada, T., & Akizawa, T. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026704 · Cited by 23
Iron metabolism and chronic inflammation in IgA nephropathy
Tian, Z.-Y., Li, Z., Chu, L., Liu, Y., He, J., Yu, X., Li, A., & Zhang, H. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2195012 · Cited by 24
Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria
Zhao, X.-N., Liu, S., Wang, Z., Zhang, S., & You, L.-L. (2023) · European journal of medical research · doi:10.1186/s40001-023-01179-3 · Cited by 27
Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo
O’Neil, R. T., Saha, S., Veach, R. A., Welch, R. C., Woodard, L. E., Rooney, C. M., & Wilson, M. H. (2018) · Nature Communications · doi:10.1038/s41467-018-03787-8 · Cited by 21
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
Akizawa, T., Taguchi, M., Matsuda, Y., Iekushi, K., Yamada, T., & Yamamoto, H. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026602 · Cited by 21
Cooperative Oxygen Sensing by the Kidney and Carotid Body in Blood Pressure Control
Patinha, D., Pijacka, W., Paton, J. F. R., & Koeners, M. P. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00752 · Cited by 22
Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives
Guedes, M. H., Robinson, B. M., Obrador, G. T., Tong, A., Pisoni, R. L., & Pecoits‐Filho, R. (2020) · Kidney360 · doi:10.34067/kid.0001442020 · Cited by 22
Insight into the binding mode of HIF-2 agonists through molecular dynamic simulations and biological validation
Yu, Y.-C., Yu, Q., Liu, S., Wu, C., & Zhang, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112999 · Cited by 21
HSP70 via HIF-1 α SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation
Peng, B., Ling, X., Huang, T., & Wan, J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294263 · Cited by 22
Erythropoietin, a putative neurotransmitter during hypoxia, is produced in RVLM neurons and activates them in neonatal Wistar rats
Oshima, N., Onimaru, H., Yamagata, A., Itoh, S., Matsubara, H., Imakiire, T., Nishida, Y., & Kumagai, H. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00455.2017 · Cited by 21
Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
Caltabiano, S., Čižman, B., Burns, O., Mahar, K. M., Johnson, B. M., Ramanjineyulu, B., Serbest, G., & Cobitz, A. R. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz013 · Cited by 21
The journey from erythropoietin to 2019 Nobel Prize: Focus on hypoxia-inducible factors in the kidney
Pan, S., Chiang, W., & Chen, Y. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.06.006 · Cited by 24
Metabolic studies of hypoxia‐inducible factor stabilisers IOX2 , IOX3 and IOX4 (in vitro) for doping control
Philip, M., Mathew, B., Karatt, T. K., Perwad, Z., Subhahar, M. B., & Kal, A. K. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3000 · Cited by 21
Identification of Hypoxia‐inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control
Mathew, B., Philip, M., Perwad, Z., Karatt, T. K., Caveney, M. R., Subhahar, M. B., & Kal, A. K. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3014 · Cited by 21
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
Chen, D., Niu, Y., Liu, F., Yang, Y., Wang, X., Li, P., & Chen, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1163908 · Cited by 24
The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review
Qie, S., Jiao, N., Duan, K., Li, J., Liu, Y., & Liu, G. (2021) · International Urology and Nephrology · doi:10.1007/s11255-020-02693-7 · Cited by 21
Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy
Lappin, K. M., Mills, K., & Lappin, T. R. J. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0387 · Cited by 18
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease
Haase, V. H., Tanaka, T., & Koury, M. J. (2024) · Hematology · doi:10.1182/hematology.2024000655 · Cited by 19
Self-citation
DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats
Kato, S., Takahashi, T., Miyata, N., & Roman, R. J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.262782 · Cited by 18
Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver
Yasuoka, Y., Izumi, Y., Fukuyama, T., Inoue, H., Oshima, T., Yamazaki, T., Uematsu, T., Kobayashi, N., Shimada, Y., Nagaba, Y., et al. (2021) · Molecules · doi:10.3390/molecules26175399 · Cited by 18
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis
Zheng, Q., Zhang, P., Yang, H., Geng, Y., Tang, J., Kang, Y., Qi, A., & Li, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15310 · Cited by 19
Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease
Solak, Y., Cetiner, M., Siriopol, D. C., Tarım, K., Afşar, B., Covic, A. C., & Kanbay, M. (2016) · Blood Purification · doi:10.1159/000446273 · Cited by 17
Oxygen sensors as therapeutic targets in kidney disease
Haase, V. H. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.015 · Cited by 18
Self-citation
Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets
Liu, C., Li, X., Zhao, Z., Chi, Y., Cui, L., Zhang, Q., Ping, F., Chai, X., Jiang, Y., Wang, O., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05649-w · Cited by 18
Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach
Moradi, Z., Maali, A., Shad, J. S., Farasat, A., Kouchaki, R., Moghadami, M., Ahmadi, M., & Azad, M. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01170-1 · Cited by 19
Treatment Options for Anemia in Kidney Transplant Patients: A Review
Bonomini, M., Liberato, L. D., & Sirolli, V. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100681 · Cited by 19
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Ishii, T., Tanaka, T., & Nangaku, M. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s293879 · Cited by 16
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor
Chavan, A. B., Burke, L., Sawant, R., Navarro‐Gonzales, P., Vargo, D. L., & Paulson, S. K. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.927 · Cited by 17
Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
Fujikawa, R., Nagao, Y., Fujioka, M., & Akizawa, T. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13820 · Cited by 17
Interleukin-22 in Renal Protection and Its Pathological Role in Kidney Diseases
Ma, Q., Luan, J., Bai, Y., Xu, C., Liu, F., Chen, B., Ju, D., & Xu, H. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.851818 · Cited by 16
The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
Sibbel, S. P., Maroni, B. J., & Brunelli, S. M. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0350-1 · Cited by 18
Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations
Sackeyfio, A., Lópes, R. D., Kovesdy, C. P., Cases, A., Mallett, S. A., Ballew, N., Keeley, T., García-Horton, V., Ayyagari, R., Camejo, R. R., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad298 · Cited by 16
Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Rink, M., Soave, A., Dahlem, R., Aziz, A., Al-Sayed, F., Peine, S., Engel, O., Kluth, L. A., Stenzl, A., Burger, M., et al. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.10.003 · Cited by 16
Investigation of FoxO3 dynamics during erythroblast development in β-thalassemia major
Thanuthanakhun, N., Nuntakarn, L., Sampattavanich, S., Anurathapan, U., Phuphanitcharoenkun, S., Pornpaiboonstid, S., Borwornpinyo, S., & Hongeng, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187610 · Cited by 16
Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation
Yasuoka, Y., Fukuyama, T., Izumi, Y., Nakayama, Y., Inoue, H., Yanagita, K., Oshima, T., Yamazaki, T., Uematsu, T., Kobayashi, N., et al. (2020) · Physiological Reports · doi:10.14814/phy2.14485 · Cited by 16
Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice
Suzuki, N., Sasaki, Y., Kato, K., Yamazaki, S., Kurasawa, M., Yorozu, K., Shimonaka, Y., & Yamamoto, M. P. (2016) · Haematologica · doi:10.3324/haematol.2015.140814 · Cited by 16
Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation
Houde, N., Beuret, L., Bonaud, A., Fortier-Beaulieu, S.-P., Truchon-Landry, K., Aoidi, R., Pic, É., Alouche, N., Rondeau, V., Schlecht‐Louf, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110223 · Cited by 16
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis
Ren, S., Zhao, Y., Wu, J., Ren, S., & Feng, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406588 · Cited by 15
Terminal Maturation of Orthochromatic Erythroblasts Is Impaired in Burn Patients
Hasan, S., Mosier, M. M., Conrad, P. F., Szilágyi, A., Gamelli, R. L., & Muthumalaiappan, K. (2017) · Journal of Burn Care & Research · doi:10.1097/bcr.0000000000000592 · Cited by 15
Absorption, distribution, metabolism and excretion of molidustat in healthy participants
Lentini, S., van der Mey, D., Kern, A., Thuß, U., Kaiser, A., Matsuno, K., & Gerisch, M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13409 · Cited by 15
Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis
Luo, D., Zhong, Z., Qiu, Y., Wang, Y., Li, H., Lin, J., Chen, W., Yang, X., & Mao, H. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.12.018 · Cited by 15
Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
Fu, Z., Geng, X., Chi, K., Song, C., Wu, D., Liu, C., & Hong, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.746265 · Cited by 15
SAR study of 1,2-benzisothiazole dioxide compounds that agonize HIF-2 stabilization and EPO production
Song, W., Zhuang, J., Zhang, N., Ren, X., Xu, W., Guo, M., Diao, X., Liu, C., Jin, J., Wu, D., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117041 · Cited by 15
Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications
Creangă, E.-C., Stan, R., Nicolae, A. C., Drăgoi, C. M., & Dumitrescu, I.-B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091190 · Cited by 14
Selective Inhibitors of a Human Prolyl Hydroxylase (OGFOD1) Involved in Ribosomal Decoding
Thinnes, C. C., Lohans, C. T., Abboud, M. I., Yeh, T., Tumber, A., Nowak, R. P., Attwood, M., Cockman, M. E., Oppermann, U. C. T., Loenarz, C., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201804790 · Cited by 13
Anemia Treatment, Hemoglobin Variability, and Clinical Events in Patients With Nondialysis-Dependent CKD in Japan
Kuragano, T., Okami, S., Tanaka‐Mizuno, S., Uenaka, H., Kimura, T., Ishida, Y., Yoshikawa‐Ryan, K., James, G., & Hayasaki, T. (2023) · Kidney360 · doi:10.34067/kid.0000000000000204 · Cited by 15
Fludrocortisone stimulates erythropoietin production in the intercalated cells of the collecting ducts
Yasuoka, Y., Izumi, Y., Nagai, T., Fukuyama, T., Nakayama, Y., Inoue, H., Horikawa, K., Kimura, M., Nanami, M., Yanagita, K., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.102 · Cited by 14
Phenotypic and proteomic characterization of the human erythroid progenitor continuum reveal dynamic changes in cell cycle and in metabolic pathways
Papoin, J., Yan, H., Leduc, M., Gall, M. L., Narla, A., Palis, J., Steiner, L. A., Gallagher, P. G., Hillyer, C. D., Gautier, E., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27145 · Cited by 13
Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
Ren, S., Yao, X., Li, Y., Zhang, Y., Tong, C., & Feng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1296702 · Cited by 13
Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
Bielach-Bazyluk, A., Małyszko, J., & Zbroch, E. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1481714 · Cited by 14
The potential role of Na-K-ATPase and its signaling in the development of anemia in chronic kidney disease
Maxwell, K., Chuang, J., Chaudhry, M. A., Nie, Y., Bai, F., Sodhi, K., Liu, J., & Shapiro, J. I. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00244.2020 · Cited by 12
Rank Order of Small Molecule Induced Hypoxiamimesis to Prevent Retinopathy of Prematurity
Hoppe, G., Bolok, Y., McCollum, L., Zhang, J., & Sears, J. E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00488 · Cited by 13
The Dawning of a New Day in CKD Anemia Care?
Lenihan, C. R., & Winkelmayer, W. C. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015091009 · Cited by 13
Roflumilast alleviates adenine-induced chronic kidney disease by regulating inflammatory biomarkers
Patel, P., Patel, S., Chudasama, P., Soni, S. M., & Raval, M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175731 · Cited by 12
Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
Tang, X., Liu, F., Li, Q., & Mao, J. (2023) · Kidney Diseases · doi:10.1159/000535071 · Cited by 12
Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Navarro‐Gonzales, P., Ganz, T., Pérgola, P. E., Zuk, A., & Dykstra, K. H. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3342 · Cited by 12
Neurogenic and pericytic plasticity of conditionally immortalized cells derived from renal erythropoietin‐producing cells
Bapst, A. M., Knöpfel, T., Nolan, K. A., Imeri, F., Schuh, C. D., Hall, A. M., Guo, J., Katschinski, D. M., & Wenger, R. H. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30677 · Cited by 11
Roxadustat, a Hypoxia-Inducible Factor 1α Activator, Attenuates Both Long- and Short-Term Alcohol-Induced Alcoholic Liver Disease
Gao, Y., Jiang, X., Yang, D., Guo, W., Wang, D., Gong, K., Peng, Y., Jiang, H., Shi, C., Duan, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.895710 · Cited by 13
Multi-scale Modelling of Erythropoiesis and Hemoglobin Production
Bouchnita, A., Rocca, A., Fanchon, É., Koury, M. J., Moulis, J., & Volpert, V. A. (2016) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-016-0437-0 · Cited by 12
Self-citation
Erythropoietin and thrombopoietin mimetics: Natural alternatives to erythrocyte and platelet disorders
Gutti, U., Pasupuleti, S. R., Sahu, I., Kotipalli, A., Undi, R. B., Kandi, R., Saladi, R. G. V., & Gutti, R. K. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.002 · Cited by 11
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF–PH inhibitor for the treatment of renal anaemia
Lentini, S., Kaiser, A., Kapsa, S., Matsuno, K., & van der Mey, D. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02813-y · Cited by 11
A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents
Nangaku, M., Kondo, K., Takabe, S., Ueta, K., Tandai, T., Kawaguchi, Y., & Komatsu, Y. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13699 · Cited by 11
Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis
Yoshida, S., Saito, T., Shibagaki, K., Hirao, K., Yuza, T., Tomosugi, N., & Honda, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-30331-6 · Cited by 10
Risk factors and current state of therapy for anemia after kidney transplantation
Tang, Y., Guo, J., Zhou, J., Wan, Z., Li, J., & Qiu, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1170100 · Cited by 10
Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia—could curcumin be of benefit?
Stenvinkel, P., & Haase, V. H. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx052 · Cited by 10
Self-citation
Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study
Akizawa, T., Nobori, K., Matsuda, Y., Hayashi, Y., Hayasaki, T., & Yamamoto, H. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13627 · Cited by 10
Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
Wang, Y., & Yu, X. (2024) · Kidney Diseases · doi:10.1159/000536039 · Cited by 14
Erythropoietin and iron—a conflicted alliance?
Ganz, T. (2018) · Kidney International · doi:10.1016/j.kint.2018.07.027 · Cited by 10
Progress in the Detection of Erythropoietin in Blood, Urine, and Tissue
Yasuoka, Y., Izumi, Y., Sands, J. M., Kawahara, K., & Nonoguchi, H. (2023) · Molecules · doi:10.3390/molecules28114446 · Cited by 12
Lipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions
Saito, K., van der Garde, M., Umemoto, T., Miharada, N., Sjöberg, J., Sigurðsson, V., Shirozu, H., Kamei, S., Radulović, V., Suzuki, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52509-w · Cited by 10
The gut–kidney axis in high-altitude hypoxia: pathophysiological mechanisms and the central role of hypoxia inducible factor
Wu, P., Li, X., Long, W., Ma, Y., Xue, B., Xie, W., & Ma, X. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2557514 · Cited by 13
Jian-Pi-Yi-Shen formula restores iron metabolism from dysregulation in anemic rats with adenine-induced nephropathy
Li, C., Huang, H., Wang, R., Zhang, C., Huang, S., Wu, J., Mo, P., Yu, H., Li, S., & Chen, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116526 · Cited by 9
The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
Zhou, Q., Mao, M., Li, J., & Deng, F. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2195011 · Cited by 12
EnvIRONmental Aspects in Myelodysplastic Syndrome
Petzer, V., Theurl, I., Weiß, G., & Wolf, D. G. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105202 · Cited by 10
Low-dose erythropoietin treatment is not associated with clinical benefits in severely anaemic Jehovah's Witnesses: a plea for a change.
Beliaev, A. M., Allen, S. J., Milsom, P., Nand, P., Smith, W. M., & Bergin, C. J. (2018) · Blood transfusion · doi:10.2450/2016.0085-16 · Cited by 9
Prevalence and morphological subtype distributions of anaemia in a Chinese rural population: the Henan Rural Cohort study
Zheng, Y., Liu, X., He, Y., Yuchi, Y., Zhao, H., Li, L., Huo, W., Mao, Z., Hou, J., & Wang, C. (2023) · Public Health Nutrition · doi:10.1017/s1368980023000319 · Cited by 8
Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients
Casimir, M., Colard, M., Dussiot, M., Roussel, C., Martinez, A., Peyssonnaux, C., Mayeux, P., Benghiat, F. S., Manceau, S., Francois, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27117 · Cited by 8
Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia
Wang, X., Wei, C., Zhao, D., Sun, X., Zhu, F., Mei, Y., Ma, Q., Cai, G., Chen, X., & Li, P. (2023) · Kidney Diseases · doi:10.1159/000533304 · Cited by 8
Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors
Takahashi, A. (2024) · Nutrients · doi:10.3390/nu16040520 · Cited by 9
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03063-1 · Cited by 9
A peptide from yak ameliorates hypoxia-induced kidney injury by inhibiting inflammation and apoptosis via Nrf2 pathway
Yang, F., Chu, Z., Wu, Q., Qu, G., He, Z., An, J., Tang, Y., Sun, S., Ci, D., & Luo, F. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104407 · Cited by 8
Anemia management in cancer patients with chronic kidney disease
Deak, A. T., Troppan, K. T., & Rosenkranz, A. R. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.08.036 · Cited by 8
Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia
Su, K., Li, Z., Zhang, L., Fang, S., Mao, M., Sun, Z., & Zhang, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114479 · Cited by 8
The expanding role of primary care providers in care of individuals with kidney disease
Martin, K. E., Thomas, B. S., & Greenberg, K. I. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.05.006 · Cited by 8
Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review
Damarlapally, N., Thimmappa, V., Irfan, H., Sikandari, M. H., MADHU, K., Desai, A., Pavani, P., Zakir, S. J., Gupta, M., Khosa, M. M., et al. (2023) · Cureus · doi:10.7759/cureus.47430 · Cited by 11
Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
Liu, C., Fu, Z., Jiang, J., Chi, K., Geng, X., Mao, Z., Song, C., Sun, G., Hong, Q., Cai, G., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.724456 · Cited by 8
Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
Song, J., Chen, X., Zhou, L., Yu, W.-H., Liu, H., & Yuan, F. (2023) · Journal of International Medical Research · doi:10.1177/03000605231204475 · Cited by 7
Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy
Jackson, W., Yang, Y., Salman, S., Dordai, D. I., Lyu, Y., Datan, E., Drehmer, D., Huang, T. Y.-T., Hwang, Y., & Semenza, G. L. (2024) · Science Advances · doi:10.1126/sciadv.adq2366 · Cited by 9
Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Yasuoka, Y., Izumi, Y., Fukuyama, T., Oshima, T., Yamazaki, T., Uematsu, T., Kobayashi, N., Nanami, M., Shimada, Y., Nagaba, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021223 · Cited by 7
Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis
Aoki, S., Saito, T., Yoshida, S., Shibagaki, K., Hirao, K., Yuza, T., & Honda, H. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04759-w · Cited by 7
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis
Wu, M., Zang, C., Ma, F., Chen, B., Liu, J., & Xu, Z. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02263-4 · Cited by 7
Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats
Naito, Y., Yasumura, S., Okuno, K., Asakura, M., Tsujino, T., Masuyama, T., & Ishihara, M. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003623 · Cited by 6

Authors: Koury, M. J., & Haase, V. H.
Affiliations: Vanderbilt University Medical Center (US)
Corresponding author: Haase, Volker H.
ORCID: Koury, Mark J.
Haase, Volker H.
Venue: Nature Reviews Nephrology
Publisher: Springer Science and Business Media LLC
Published: 2015-06-09
Volume: 11
Issue: 7
Pages: 394-410
ISSN: 1745-8323 (ISSN-L)
1759-5061
1759-507X
DOI: 10.1038/nrneph.2015.82
PMC: PMC4497972
OpenAlex: W1893364029
Cited by: 313
References: 239
Citations by year: 2026: 20 · 2025: 28 · 2024: 26 · 2023: 39 · 2022: 45 · 2021: 36 · 2020: 31 · 2019: 20 · 2018: 22 · 2017: 20 · 2016: 20 · 2015: 5
FWCI: 3.34
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Nephrology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Department of Veterans Affairs (I01 BX002348)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080821, R01DK101791, R01DK081646)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
Keywords: anemia of chronic kidney disease, erythropoiesis, erythropoietin, hypoxia-inducible factor, HIF-2, iron metabolism, inflammation, iron deficiency, renal failure, hepatocytes, oxygen sensing
MeSH terms: Endothelial PAS Domain-Containing Protein 1, Anemia, Erythropoiesis, Humans, Signal Transduction, Cell Hypoxia, Renal Insufficiency, Chronic, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anaemia in kidney disease: harnessing hypoxia responses for therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks